AgeX Therapeutics (NYSE:AGE) shares shot up 5.3% during trading on Wednesday . The company traded as high as $2.80 and last traded at $2.77, 121,599 shares traded hands during mid-day trading. An increase of 48% from the average session volume of 82,319 shares. The stock had previously closed at $2.63.
The firm has a fifty day moving average of $2.68 and a 200 day moving average of $3.54. The company has a current ratio of 2.54, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03.
Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new position in AgeX Therapeutics in the fourth quarter valued at approximately $366,000. Deutsche Bank AG acquired a new stake in shares of AgeX Therapeutics during the 4th quarter worth approximately $37,000. Sigma Planning Corp acquired a new stake in shares of AgeX Therapeutics during the 1st quarter worth approximately $139,000. Price Capital Management Inc. increased its holdings in shares of AgeX Therapeutics by 62.5% during the 1st quarter. Price Capital Management Inc. now owns 113,973 shares of the company’s stock valued at $461,000 after purchasing an additional 43,851 shares in the last quarter. Finally, Iowa State Bank purchased a new position in shares of AgeX Therapeutics during the 2nd quarter valued at approximately $40,000. Institutional investors own 16.88% of the company’s stock.
AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.
Further Reading: Channel Trading
Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.